RSS   Newsletter   Contact   Advertise with us
Post Online Media
Post Online Media Magazine

Midatech Pharma US appoints two managers

Share on Twitter Share on LinkedIn
Christian Fernsby | Raleigh, N.C., USA | June 25, 2019
Midatech PharmaMidatech Pharma US, an oncology company, has changed its name to Fortovia Therapeutics and made two strategic executive hires to strengthen its leadership team.
Peter Melnyk has joined the Fortovia team as its Chief Executive Officer, bringing over 25+ years of oncology experience.

Prior to Fortovia, Mr. Melnyk served as Chief Commercial Officer of Novocure Inc., with overall responsibility for directing global sales and marketing efforts and the global launch of Optune.

Mr. Melnyk was previously Senior Vice President for global sales and marketing at OSI Pharmaceuticals, Inc., where he led the global commercialization efforts and the launch of Tarceva.

He was also previously Executive Director of Oncology at Pharmacia/Pfizer Inc. and a Director of Oncology at Bristol-Myers Squibb.

Mr. Melnyk started his career with Leo Laboratories and Burroughs-Welcome in Canada.

Mr. Melnyk holds a B.Sc. and M.Sc. from McGill University.

Ernest De Paolantonio has joined the Company as its Chief Financial Officer.

Mr. De Paolantonio previously served as Chief Financial Officer of BioDelivery Sciences International, a publicly traded pharmaceutical company with three-marketed specialty branded products.

Mr. De Paolantonio received his B.A. from Lycoming College; his MBA in Finance from Saint Joseph's University and is also a C.P.A.


 LATEST MOVES FROM North Carolina 


POST Online Media Contact